Form Bio and Ginkgo Bioworks have unveiled an innovative collaboration to revolutionize AAV gene therapy design and development. This partnership combines Ginkgo's expertise in cell programming and biosecurity with Form's advanced computational life sciences solutions, aiming to simplify the gene therapy development process and accelerate the delivery of safer and more effective treatments to patients.

The collaboration integrates Ginkgo's licensable assets, such as cell lines and foundry capabilities, with Form's renowned in silico solutions for characterization, simulation, and AI-driven construct design optimization. By providing a comprehensive solution for gene therapy developers, the partnership seeks to reduce time-to-clinic and conserve capital.

Form Bio, highlighted the potential of AI to significantly reduce preclinical development time, enabling faster delivery of life-saving treatments at lower costs. He emphasized that the combined capabilities of AI and integrated manufacturing modeling, alongside Ginkgo's industry-leading AAV products and services, offer clients a comprehensive solution for accelerated AAV therapeutic development.

Ginkgo Bioworks, expressed excitement about having Form Bio as an inaugural partner in their Technology Network, citing Form Bio's expertise in AI and innovative in silico techniques as transformative for gene therapy development. He emphasized the value that this collaboration brings to customers seeking to leverage advances in generative AI in a fully integrated manner.

While the focus of the partnership is on gene therapy, both companies offer broad capabilities across nucleic acids, delivery platforms, and therapeutic modalities. With over 2,000 gene therapies currently in development, as reported by ASGCT and Citeline, the challenges of designing safe, effective, and manufacturable therapeutic products remain significant. However, the partnership between Form Bio and Ginkgo Bioworks aims to address these challenges head-on, providing a holistic solution to advance the field of gene therapy.

 

Source: accesswire.com

Report Abuse